Face masks to prevent transmission of respiratory infections: Systematic review and meta-analysis of randomized controlled trials on face mask use.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2022
Historique:
received: 05 08 2021
accepted: 04 07 2022
entrez: 1 12 2022
pubmed: 2 12 2022
medline: 6 12 2022
Statut: epublish

Résumé

To examine the use of face mask intervention in mitigating the risk of spreading respiratory infections and whether the effect of face mask intervention differs in different exposure settings and age groups. Systematic review and meta-analysis. We evaluated the risk of bias using the Cochrane Risk of Bias 2 tool (ROB2). We searched PubMed, Embase, Cochrane Central Register of Controlled Trials, and Web of Science were searched for randomized controlled trials investigating the effect of face masks on respiratory infections published between 1981 and February 9, 2022. We followed the PRISMA 2020 guidelines. We included randomized controlled trials investigating the use of face mask intervention in mitigating the risk of spreading respiratory infections across different exposure settings. We identified 2,400 articles for screening. 18 articles passed the inclusion criteria for both evidence synthesis and meta-analysis. There were N = 189,145 individuals in the face mask intervention arm and N = 173,536 in the control arm, and the follow-up times ranged from 4 days to 19 months. Our results showed between-study heterogeneity (p < 0.0001). While there was no statistically significant association over all studies when the covariate unadjusted intervention effect estimates were used (RR = 0.977 [0.858-1.113], p = 0.728), our subgroup analyses revealed that a face mask intervention reduced respiratory infections in the adult subgroup (RR = 0.8795 [0.7861-0.9839], p = 0.0249) and in a community setting (RR = 0.890 [0.812-0.975], p = 0.0125). Furthermore, our leave-one-out analysis found that one study biased the results towards a null effect. Consequently, when using covariate adjusted odds ratio estimates to have a more precise effect estimates of the intervention effect to account for differences at the baseline, the results showed that a face mask intervention did reduce respiratory infections when the biasing study was excluded from the analysis (OR = 0.8892 [0.8061-0.9810], p = 0.0192). Our findings support the use of face masks particularly in a community setting and for adults. We also observed substantial between-study heterogeneity and varying adherence to protocol. Notably, many studies were subject to contamination bias thus affecting the efficacy of the intervention, that is when also some controls used masks or when the intervention group did not comply with mask use leading to a downward biased effect of treatment receipt and efficacy. PROSPERO registration number CRD42020205523.

Identifiants

pubmed: 36454947
doi: 10.1371/journal.pone.0271517
pii: PONE-D-21-23020
pmc: PMC9714953
doi:

Types de publication

Meta-Analysis Systematic Review Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0271517

Informations de copyright

Copyright: © 2022 Ollila et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Influenza Other Respir Viruses. 2011 May;5(3):170-9
pubmed: 21477136
Science. 2022 Jan 14;375(6577):eabi9069
pubmed: 34855513
Prev Med. 2014 May;62:1-7
pubmed: 24472436
Nat Med. 2020 Sep;26(9):1417-1421
pubmed: 32665655
Emerg Infect Dis. 2009 Feb;15(2):233-41
pubmed: 19193267
Am J Infect Control. 2009 Jun;37(5):417-419
pubmed: 19216002
PLoS One. 2008 May 07;3(5):e2101
pubmed: 18461182
Ann Intern Med. 2021 Mar;174(3):335-343
pubmed: 33205991
Cochrane Database Syst Rev. 2020 Nov 20;11:CD006207
pubmed: 33215698
BMJ. 2019 Aug 28;366:l4898
pubmed: 31462531
N Engl J Med. 2020 Apr 16;382(16):1564-1567
pubmed: 32182409
BMJ Open. 2015 Apr 22;5(4):e006577
pubmed: 25903751
Influenza Other Respir Viruses. 2011 Jul;5(4):256-67
pubmed: 21651736
PLoS One. 2012;7(1):e29744
pubmed: 22295066
Am Fam Physician. 2021 Jan 1;103(1):16-18
pubmed: 33382567
PLoS One. 2010 Nov 17;5(11):e13998
pubmed: 21103330
Lancet. 2021 May 1;397(10285):1603-1605
pubmed: 33865497
PLoS One. 2020 Oct 13;15(10):e0240287
pubmed: 33048964
Cochrane Database Syst Rev. 2013 Jan 31;(1):CD004816
pubmed: 23440795
Public Health Rep. 2010 Mar-Apr;125(2):178-91
pubmed: 20297744
J Infect Dis. 2010 Feb 15;201(4):491-8
pubmed: 20088690
BMC Infect Dis. 2012 Jan 26;12:26
pubmed: 22280120
Infect Disord Drug Targets. 2014;14(2):110-6
pubmed: 25336079
BMJ. 2009 Jul 21;339:b2535
pubmed: 19622551
Proc Math Phys Eng Sci. 2020 Jun;476(2238):20200376
pubmed: 32821237
BMC Med Res Methodol. 2019 Jan 7;19(1):4
pubmed: 30616508
J Educ Health Promot. 2020 Jul 28;9:192
pubmed: 33015206
Lancet. 2020 Jun 27;395(10242):1973-1987
pubmed: 32497510
BMJ Open. 2016 Dec 30;6(12):e012330
pubmed: 28039289
Emerg Infect Dis. 2020 Jun;26(6):1320-1323
pubmed: 32125269
JAMA. 2020 Oct 20;324(15):1495-1496
pubmed: 33044484
Am Fam Physician. 2017 Apr 1;95(7):422-423
pubmed: 28409601
Ann Intern Med. 2009 Oct 6;151(7):437-46
pubmed: 19652172
Am Fam Physician. 2010 Jul 1;82(1):42
pubmed: 20590068
Travel Med Infect Dis. 2020 Jul - Aug;36:101751
pubmed: 32473312
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120

Auteurs

Hanna M Ollila (HM)

Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.
Broad Institute of MIT and Harvard, Cambridge, MA, United States of America.
Center for Genomic Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States of America.
Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, MA, United States of America.

Markku Partinen (M)

Helsinki Sleep Clinic, Terveystalo Healthcare, Helsinki, Finland.
Department of Clinical Neurosciences, Clinicum, University of Helsinki, Helsinki, Finland.

Jukka Koskela (J)

Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.
Broad Institute of MIT and Harvard, Cambridge, MA, United States of America.
Helsinki University and Helsinki University Hospital, Clinic of Gastroenterology Helsinki, Helsinki, Finland.

John Borghi (J)

Lane Medical Library, Stanford University School of Medicine, Stanford, California, United States of America.

Riikka Savolainen (R)

Swansea University, Swansea, United Kingdom.

Anna Rotkirch (A)

Population Research Institute, Väestöliitto, The Family Federation of Finland, Helsinki, Finland.

Liisa T Laine (LT)

University of Missouri, Columbia, MO, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH